STOCKHOLDERS’ EQUITY (Tables)

12 Months Ended

Dec. 31, 2025

Equity [Abstract]

SCHEDULE OF SHARE CAPITAL

The Company had the following common share transactions during the year ended December 31, 2025:

		No. of shares				Amount
Shares issued for conversion of convertible debt			2,784,169			$	16,186,143
Shares issued for cash at the market, net of issuance costs			494,390				1,447,737
Shares issued in the offering, net of issuance costs			87,699,328				198,449,318
Shares issued for compensation, vested			804,445				1,795,671
Shares issued for consulting services, vested			935,641				228,969
Shares issued on exercise of warrants			231,920				403,061
Repurchases of shares			(183,346	)			(257,964	)
Total common shares issued			92,766,547			$	218,252,935

The Company had the following common share transactions during the year ended December 31, 2024:

		No. of shares				Amount
Shares issued for conversion of convertible debt			99,443			$	11,469,407
Shares issued for cash			59,651				2,775,616
Shares issued for compensation			950				115,639
Shares issued for consulting services			158				27,624
Shares issued for business combination			5,556				295,000
Shares issued on conversion of vested pre-funded warrants			7				530,429
Total common shares issued			165,765			$	15,213,715

SCHEDULE OF OUTSTANDING WARRANTS

The Company’s outstanding warrants as of December 31, 2025, were:

		No. of warrants				Weighted average exercise price				Expiration Date
						$
Outstanding, December 31, 2023			3,197				2,314.07
Granted February 21, 2024			3,712				10.00	(a), (b)		August 21, 2027
Granted April 11, 2024			2,437				10.00	(a), (b)		October 11, 2027
Granted May 22, 2024			6,016				11.00	(a), (b)		November 22, 2027
Expired July 16, 2024			(72	)			30,000.00
Outstanding, December 31, 2024			15,291				351.57
Granted January 16, 2025			212,256				25.94			July 16, 2028
Granted March 21, 2025			47,906				17.91			September 21, 2028
Granted May 21, 2025			4,889				17.91			November 21, 2028
Granted July 21, 2025			80,354				6.74			January 21, 2029
Granted September 25, 2025			148,340				2.65			September 25, 2029
Granted October 24, 2025			2,076,763				2.41			April 24, 2029
Exercised			(260,797	)			2.36
Expired			(170	)			115,372.69
Outstanding, December 31, 2025			2,324,832				2.36

	(a)	The issuance of the Seventh Tranche Debenture on May 22, 2024 triggered the down-round provision, adjusting the exercise prices of the Debenture Warrants to $10.00 (Note 10).

	(b)	On January 16, 2025, institutional investors purchased $7,700,000 of convertible debt and warrants were issued with an exercise price of $2.62 per share. The issuance of the additional tranche triggered the round down provision, adjusting the exercise price of the First, Second, Third, Fourth, Fifth, Sixth, and Seventh Tranche Debentures and First, Second, Third, Fourth, Fifth, Sixth, and Seventh Tranche Warrants to $2.62.

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE

The following table sets forth the computation of basic and diluted net loss per share:

		December 31, 2025				December 31, 2024
Basic net loss per share:
Numerator
Net loss from continuing operations		$	(31,994,535	)		$	(15,871,753	)
Net loss from discontinued operations		$	(1,200,671	)		$	(403,062	)
Net loss		$	(33,195,206	)		$	(16,274,815	)
Denominator
Basic weighted-average common shares outstanding			16,390,876				79,292
Basic net loss per share for continuing operations		$	(1.95	)		$	(200.17	)
Basic net loss per share for discontinued operations		$	(0.07	)		$	(5.08	)
Basic net loss per share, total		$	(2.03	)		$	(205.25	)

Diluted net loss per share:
Numerator
Net loss from continuing operations		$	(31,994,535	)		$	(15,871,753	)
Net loss from discontinued operations		$	(1,200,671	)		$	(403,062	)
Net loss		$	(33,195,206	)		$	(16,274,815	)
Change in fair value of convertible debenture warrants		$	(2,560,523	)		$	(1,890,135	)
Diluted net loss		$	(35,755,729	)		$	(18,164,950	)
Denominator
Number of shares used in basic net loss per share computation			16,390,876				79,292
Weighted-average effect of potentially dilutive securities:
Convertible warrants			255,649				11,757
Diluted weighted-average common shares outstanding			16,646,525				91,049
Diluted net loss per share for continuing operations		$	(2.08	)		$	(195.08	)
Diluted net loss per share for discontinued operations		$	(0.07	)		$	(4.43	)
Diluted net loss per share, total		$	(2.15	)		$	(199.51	)

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

Potentially dilutive securities that are not included in the calculation of diluted net loss per share because their effect is anti-dilutive are as follows (in common equivalent shares):

		December 31, 2025				December 31, 2024
Warrants			2,324,832				15,291
Options			-				61
Convertible debentures			3,909,958				650,726
Total anti-dilutive weighted average shares			6,234,790				666,078